Drug studies in humans
Last updated: 2024 May 18
Total hit(s): 6693
S.No.
1
38512394
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
2
38584118
Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
3
38714327
Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
4
38346223
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
5
38575149
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
6
38073167
Assessing the quantity of neuropeptide Y in the serum of patients referred to Baqiyatallah Hospital with covid-19 concerning inflammatory factors following steroid therapy.
Acta Neurol Taiwan
2024 Dec 30
1
7
38183475
Development of multiplex allele-specific RT-qPCR assays for differentiation of SARS-CoV-2 Omicron subvariants.
Appl Microbiol Biotechnol
2024 Dec
3.82
1
8
38717195
Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients.
Virulence
2024 Dec
4.81
1
9
38377136
Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies.
Emerg Microbes Infect
2024 Dec
5.84
1
10
38653156
Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
Virology
2024 Jul
2.819
1
11
38636235
Understanding treatment of pain during SARS-CoV-2 pandemic in a two-year intercity longitudinal study using wastewater-based epidemiology.
J Hazard Mater
2024 Jun 5
14.6
1
12
38379717
An efficient ELISA protocol for measurement of SARS-CoV-2 spike-specific IgG in human plasma and serum samples.
MethodsX
2024 Jun
1
13
38643592
The AI ethics of digital COVID-19 diagnosis and their legal, medical, technological, and operational managerial implications.
Artif Intell Med
2024 Jun
1
14
38634071
SARS-CoV-2 variant typing using real-time reverse transcription-polymerase chain reaction-based assays in Addis Ababa, Ethiopia.
IJID Reg
2024 Jun
1
15
38655560
Genomic surveillance of SARS-CoV-2 in North Africa: 4 years of GISAID data sharing.
IJID Reg
2024 Jun
1
16
38677126
A novel linear B cell epitope of the canine coronavirus nucleocapsid protein identified by a monoclonal antibody.
Vet Microbiol
2024 Jun
2.82
1
17
38524302
Alternative genome sequencing approaches of SARS-CoV-2 using Ion AmpliSeq Technology.
MethodsX
2024 Jun
1
18
38652363
Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach.
Daru
2024 Jun
2.72
1
19
38574505
Diverse pro-inflammatory ability of mutated spike protein derived from variant strains of SARS-CoV-2.
Cytokine
2024 Jun
2.88
1
20
38721746
Genetic Polymorphism of Interleukin-6 in Asymptomatic and ICU-Admitted COVID-19 Patients in Sulaymaniyah Province, Kurdistan Region of Iraq.
Genet Test Mol Biomarkers
2024 May 9
1
21
38724525
Genomic characterization of Influenza A (H1N1)pdm09 and SARS-CoV-2 from Influenza Like Illness (ILI) and Severe Acute Respiratory Illness (SARI) cases reported between July-December, 2022.
Sci Rep
2024 May 9
4.12
1
22
38722338
Quantitative assay to analyze neutralization and inhibition of authentic Middle East respiratory syndrome coronavirus.
Med Microbiol Immunol
2024 May 9
6.7
1
23
38721724
Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
Int J Cancer
2024 May 9
5.07
1
24
38715342
Chlamydia psittaci Pneumonia: Diagnosis, Treatment, and Challenges in the Context of COVID-19.
Am J Case Rep
2024 May 8
0.69
1
25
38686454
Interface design of SARS-CoV-2 symmetrical nsp7 dimer and machine learning-guided nsp7 sequence prediction reveals physicochemical properties and hotspots for nsp7 stability, adaptation, and therapeutic design.
Phys Chem Chem Phys
2024 May 8
6.3
1